Senses Disorder TRIZ Cases

4-Alkynyl-4-hydroxy-2-azabicyclo[3.1.0]hexan-3-one compounds inhibit NIK kinase activity.

Formula I compounds use electrophilic warheads to covalently bond with PAD4 catalytic cysteine residues for targeted inhibition.

Laquinimod raises BDNF serum concentrations to address low trophic factor deficits in Huntington's disease therapy.

Structural modifications of 6-shogaol enhance Nrf2 activation potency and HO-1 expression for treating oxidative stress diseases.

Segmented sd-rxRNAs with localized chemical modifications resolve the contradiction between gene silencing reliability and cellular uptake efficiency.

Humanized anti-KDR antibodies bind VEGFR2 with high affinity, blocking receptor signaling to overcome resistance to VEGF blockade therapies.

Optimized recrystallization resolves contradictions between manufacturing precision and process complexity while reducing material loss.

Oxalate compounds activate TRPM8 ion channels to induce a cooling sensation on human skin and mucosa.

Viral vector gene delivery of COX-2 and receptors reduces intraocular pressure by 38% while treating cardiovascular and renal disease progression.

A tanfanercept-containing ophthalmic composition treats dry eye syndrome by delivering a stable polypeptide to the ocular surface.

Novel diazaheterobicyclic structures selectively inhibit TASK-1 and TASK-3 channels, resolving the trade-off between treatment efficacy and channel specificity.

Topical citicoline bypasses hepatic metabolism to sustain neuroprotective concentrations at the optic nerve head.

Selective pyridine derivatives act as S1P1 receptor agonists to modulate immune responses.

PPPT compounds inhibit 11β-HSD1 enzyme activity, addressing the lack of stable inhibitors for metabolic syndrome and type 2 diabetes.

Phosphonium compounds enter nociceptors via TRPV1 channels to block sodium channels.

Triazole-based small molecules enhance Kv3 channel selectivity while optimizing pharmacokinetic profiles for safe, prolonged oral administration.

Controlled ATP treatment and cytoplasmic reduction induce pluripotency in adult cells, bypassing complex exogenous reprogramming factors.

Sequential neural media differentiation overcomes low reproducibility in synthetic retina formation to yield functional photoreceptor outer segments.

An ActRII antagonist polypeptide increases red blood cell levels by inhibiting the ActRII signaling pathway.

Stabilizing HIF-1α via PHD inhibitors prevents retinal vascular destruction during hyperoxia, resolving the contradiction between survival and ROP progression.

Heterocyclic derivatives block 11beta-HSD1 conversion of cortisone to cortisol, addressing insufficient therapeutic effectiveness in metabolic disorders.

Thienotriazolodiazepine compound blocks CD28 costimulatory signal to induce antigen-specific immunological tolerance without broad immune suppression.

Bilastine cocrystals with glutaric acid enhance aqueous solubility, enabling stable parenteral formulations.

Specific indole derivatives inhibit beta-amyloid aggregation to rescue retinal ganglion cells in glaucoma.

Targeting FcRn reduces pathogenic autoantibody half-life and mitigates immune complex activation.

Intratympanic auris formulations bypass the blood-labyrinth-barrier to provide targeted drug delivery while maintaining ionic balance compatibility.

A biodegradable lens-shaped patch delivers amniotic extracts to the cornea.

Selective mGluR1 antagonism reduces chronic pain side effects by sparing normal excitatory synaptic transmission.

Substituted pyrrolidine compounds inhibit renin activity via specific structural modifications, reducing adverse effects from non-specific targeting.

Temperature-sensitive elastin-like polypeptides fuse with therapeutic proteins to extend ocular residence time.

A synergistic ophthalmic composition combining pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, and bromfenac to improve near vision.

Chiral catalysts synthesize antifungal compounds with specific metal-binding groups to balance potency and selectivity against metalloenzymes.

Pyridyl amide compounds modulate the histamine H3 receptor to address insufficient therapeutic effectiveness of existing antagonists.

Cordyceps cicadae mycelium active substances mitigate steroid-induced ocular side effects by reducing histopathological changes in the eye.

A specific peptide sequence inhibits T cell migration to treat autoimmune conditions.

Combination of L-carnitine, Coenzyme Q10, and omega-3 fatty acids treats corneal diseases.

Recombinant Norrin compound activates Wnt signaling to promote retinal vascularization and cell proliferation.

A porous, laminin-coated membrane supports retinal pigmented epithelial cell growth and nutrient diffusion.

An rAAV8 vector delivers anti-VEGF antibody fragments to retinal cells, reducing injection frequency and cumulative ocular risks.

Disulfiram blocks neutrophil pyroptosis, preventing NET release and IL-1β discharge that delay corneal wound healing after chemical burns.

A GP73 inhibitor binds soluble glucagon to lower blood glucose levels and protect islet beta cells.

Replacing methylsulfonyl groups with SO2R substituents on the benzene ring improves in vivo potency and pharmacokinetic profiles of CRTH2 antagonists.

Specific structural modifications reduce CB1 activity, resolving the trade-off between therapeutic efficacy and adverse effects.

Optimized human antibodies targeting CD20 antigens deliver potent cytotoxic effects at low concentrations, extending symptom-free survival in lymphoma models.

Synthetic triterpenoids activate the Keap1/Nrf2/ARE pathway to reduce serum creatinine levels and improve glomerular filtration rate.

A PEG capsule with a porous sheet releases therapeutic drugs through controlled diffusion for sustained ocular treatment.

Aromatic heterocyclic compounds inhibit diacylglycerol O-acyltransferase 1 activity to reduce triglyceride accumulation.